INTRODUCTION
Diffuse lung disease in children, including interstitial lung disease (ILD) and chronic lung disease, is a rare heterogeneous group of chronic disorders characterized by impaired gas exchange 1 . Recent studies suggest that surfactant deficiency plays a role in the pathogenesis 2 .
Pulmonary surfactant is a complex mixture of proteins and lipids that prevents collapse at end expiration by reducing surface tension at the air-water interface of the lung alveoli.
Surfactant protein C (SP-C), a hydrophobic protein critically involved in surfactant homeostasis 3 , is expressed by alveolar type II epithelial cells and encoded by a single gene in the skipping of exon 4 and the deletion of 37 amino acids in the carboxy-terminal domain of proSP-C. This mutation was observed in one allele of a patient suffering from chronic interstitial pneumonitis and was inherited following a dominant pattern. To date, 13 SFTPC mutations have been identified [4] [5] [6] [7] [8] [9] [10] [11] . They always occur in one single allele and have been associated with diffuse lung disease in children and adults. The mutation I73T (c.218 T>C) is the more prevalent mutation; others have been described in only one family. Dominant transmission with variable penetrance has been confirmed in familial cases, but a number of sporadic cases have also been reported with a de novo mutation. The phenotype associated with SFTPC mutations appears to be very variable. Indeed, neonatal forms leading to death in the first years of life as well as childhood and adult forms with chronic respiratory disease have been reported. Single nucleotide polymorphisms (SNPs) have also been detected both in the coding and non-coding sequence, with unclear consequences on proSP-C processing and function 2 .
The variable phenotype with unspecific biological findings makes the genetic diagnosis of SP-C inherited disease essential. Thus, the present study aims to investigate SFTPC variations in a large population of 121 children (120 unrelated) with diffuse lung disease and suspected surfactant dysfunction.
MATERIALS AND METHODS

Patients
One hundred and twenty-one newborns/children (60 male, 61 female) diagnosed with The 121 patients where the common 121ins2 SFTPB mutation was initially ruled out were analyzed for the common I73T mutation. Then, the entire SFTPC coding sequence was performed in patients without the I73T mutation.
Mutation Analysis
Genomic DNAs were extracted from patients' blood using an automated BioRobot EZ1
workstation (Qiagen, Hilden, Germany). The common mutation I73T was screened using an allele specific amplification as previously published 12 
RESULTS
We screened a cohort of 121 patients with diffuse lung disease for the mutation c.218T>C (p.Ile73Thr, I73T). SFTPC mutation is present in 18 (17 unrelated) patients and seven novel mutations are described.
The I73T mutation was found in 10 patients without neonatal onset, eight presenting with respiratory viral infection. I73T was inherited in 6 cases. In 4 cases, I73T was sporadic and thus absent in both parents. The 111 patients without I73T mutation were screened for all the coding sequence and the exon-intron boundaries of SFTPC. Seven novel SFTPC variations were identified (Table 1) . Interestingly, the age of onset was significantly lower in patients with new mutations compared with those carrying the I73T mutation (Table 2) . No other significant differences between the two groups of patients were observed. 
DISCUSSION
The identification of SP-C alterations has led to significant advances in the diagnosis of diffuse lung disease. Our study on a large cohort of patients confirms that the common mutation I73T in the SFTPC gene is a frequent cause of diffuse lung disease. In addition, we described seven new pathogenic SFTPC variants associated with respiratory diseases occurring during the first months of life.
The mutation I73T has been first reported in one allele of an infant with severe respiratory insufficiency and a histological pattern of nonspecific interstitial pneumonia (NSIP) and pulmonary alveolar proteinosis (PAP) 7, 9 . Furthermore, in a cohort of 116 children with ILD, this mutation was present in 7 cases and appeared to be common 12 . The mutation was inherited or observed de novo. The phenotype associated with I73T was described as eminently variable, ranging from fatal cases to asymptomatic adult carriers 12, 13 . In our cohort of 121 patients with diffuse lung disease, we found 10 unrelated patients with diffuse lung disease harboring the I73T mutation. This result confirms the high frequency of this mutation in diffuse lung disease.
Besides this frequent mutation, only 12 SFTPC mutations have been previously described. We report in this study seven new mutations. The splice site mutation c.325-1G>A is thought to affect the acceptor splice site of exon 4, and may result in the skipping of exon 4.
Thus, this mutation probably has the same effect than the previously reported mutation c.435+1G>A affecting the donor site of exon 4 4 . The deletion c.424delC induces the translation of an abnormal protein. The missense mutations V39A, Q145H, L188P, C189Y, and L194P are believed to be pathogenic because they have not been observed in control chromosomes of the same origin. Moreover, the amino acids involved are conserved in mammalian SP-C sequences, and the mutation segregates with the pulmonary disease in familial cases (C189Y and L194P).
The phenotype associated with C189Y appeared to be variable, severe in the first months of life and asymptomatic in adults. In contrast, L194P is associated with pulmonary fibrosis in adults.
The mutation V39A is the first valine of the polyvaline stretch of mature SP-C. The polyvaline stretch is believed to be a crucial actor of the secondary structure of SP-C. Indeed, studies of purified mature SP-C have shown that the polyvaline stretch is highly α -helical and capable of spanning phospholipids bilayers in the liquid crystalline phase 14 .
To date, most of the mutations previously identified in the SP-C gene are localized in the propeptide. In our study, with the exception of the V39A located in the mature peptide, the other new mutations are in the propeptide. Based on functional studies that ascertain the role of SFTPC mutations in the pathogenesis of diffuse lung disease, two mechanisms have been suggested 2, 10 . First, owing to a heterozygous mutation, abnormal proSP-C could disrupt the regular processing of proSP-C within the cell and consequently inhibit SP-C production in the alveoli. This is the case for the I73T and E66K mutations altering intracellular trafficking 7, 10 .
Also, as shown in the Δexon4 and L188Q mutations, aberrant proSP-C forms aggregates that could be toxic for alveolar type II cells and induce an unresolved inflammatory response [15] [16] [17] .
Moreover, in two patients, diffuse lung disease have also been associated with SP-C deficiency without any detectable SFTPC mutation 9 . Thus, Alteration of SP-C metabolism or complete SP-C deficiency is critical in diffuse lung disease pathophysiology.
Interestingly, we found three novel variants, L188P, C189Y and L194P, located in the C-terminus of proSP-C BRICHOS domain (F94-I197)-a highly conserved domain. The BRICHOS domain is composed of about 100 amino acids in the proprotein. It is found in several proteins associated with degenerative and proliferative diseases 18 . The BRICHOS domain is thought to be involved in protein processing and is assumed to have a chaperone-like function. It plays a critical role in proSP-C targeting and processing 16, 19, 20 . Indeed, in previous studies, two patients have been found to carry a mutation encoding substitution (L188R and L188Q) of the same conserved leucine residue altered in our cohort (L188P). The L188R mutation has been detected in one infant with ILD 5 . On the other hand, the L188Q mutation is detected in large familial pulmonary fibrosis kindred, either in children or adults with cellular interstitial pneumonitis or usual interstitial pneumonitis 6 . We have observed L188P in an 18-year-old patient who had diffuse lung disease during the first year of life. Unfortunately, familial samples were not available.
Descriptions of the reported new mutations will be the subject of further functional studies, which will improve knowledge on the pathogenesis of associated surfactant diffuse lung disease in children. 
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